Summary: A new study from the University of Rochester shows that transplanting healthy human glial progenitor cells into adult mice modeling Huntington’s disease delays motor and cognitive decline and extends survival. The transplanted glia restored neuronal gene expression, repaired synaptic structure, and improved behavioral outcomes even when treatment began after symptoms appeared.
Huntington’s disease has long been treated as a disorder driven primarily by failing neurons. This research highlights a complementary and critical role for glial cells in disease progression and suggests that glial-based cell therapies may offer a promising avenue for adult brain repair.
Key facts:
- Beyond neurons: Dysfunction in glial cells contributes substantially to Huntington’s progression.
- Restorative potential: Transplanted human glia improved motor skills, memory measures, and neuronal structure in treated mice.
- Adult brain repair: Benefits were observed even when transplantation occurred after initial symptoms had appeared.
Institution: University of Rochester
Researchers led by Steve Goldman, MD, PhD, co-director of the University of Rochester Center for Translational Neuromedicine, report that introducing healthy human glial progenitor cells (hGPCs) into the striata of adult R6/2 mice—the widely used Huntington’s disease model—produced measurable and meaningful improvements. The study, published in Cell Reports, used behavioral testing, single-nucleus RNA sequencing, and neuronal labeling techniques to evaluate outcomes.
“Glia are essential caretakers of neurons,” said Goldman. According to the team, restoring healthy glial support in symptomatic animals reset neuronal gene expression, stabilized synaptic function, and significantly delayed disease progression. The results expand the view of Huntington’s pathology from a strictly neuron-centric disease to one in which glial dysfunction drives synaptic failure and clinical decline.
Huntington’s disease and the role of glia
Huntington’s disease is an inherited neurodegenerative disorder caused by a mutation in the huntingtin gene that produces an abnormal protein, gradually damaging neurons—especially in the striatum—and leading to movement disorders, mood disturbances, and cognitive loss. Historically, therapeutic efforts have focused on protecting or replacing neurons. However, glial cells—once considered passive support—are now known to regulate neuronal health, control inflammation, and maintain the brain’s chemical balance. When glia malfunction in Huntington’s disease, they can exacerbate neuronal injury.
Replacing diseased glia with functioning human glial progenitor cells aims to recreate the supportive environment neurons need. The transplanted hGPCs can mature into multiple glial types and restore the extracellular milieu required for synaptic maintenance and neuronal signaling.
Study design: transplanting healthy glia into symptomatic mice
The investigators used R6/2 mice, which develop motor and cognitive symptoms similar to those observed in Huntington’s patients. At five weeks of age—when early symptoms are present but before severe decline—mice received intrastriatal injections of human glial progenitor cells. The team assessed coordination, movement, memory, and anxiety-related behavior over time.
To probe cellular and molecular changes, researchers applied single-nucleus RNA sequencing (snRNA-seq) to profile gene expression in striatal neurons and used a modified rabies virus to label individual neurons and visualize dendritic branching and spine density.
Findings: motor benefit, gene restoration, and synaptic repair
Treated mice experienced a measurable delay in motor and cognitive decline and survived significantly longer than untreated HD mice. At the molecular level, snRNA-seq revealed that genes involved in synaptic development and structure—normally downregulated in R6/2 striatal neurons—were partially reactivated following glial engraftment. Structurally, rabies labeling showed that dendritic complexity and spine density, which are typically reduced in R6/2 neurons, were largely restored in animals that received hGPCs.
Co-author Abdellatif Benraiss, PhD, emphasized that meaningful improvements were observed even though treatment began after symptoms were already present, underscoring the potential for interventions in adults rather than only in neonatal models.
Implications and future directions
The authors propose that glial replacement could become part of a broader Huntington’s disease treatment strategy—alone or combined with gene-targeting therapies and neuron replacement approaches. Remaining challenges include optimizing delivery, dosing, timing, and combining glial transplantation with other therapeutic modalities to maximize benefit. While mouse models do not capture every aspect of human Huntington’s disease, these results broaden the therapeutic landscape to include glial repair as an attractive, clinically relevant option.
Additional contributors to the paper include co-first authors Carlos Villanueva and Nguyen Huynh and other members of the Center for Translational Neuromedicine from the University of Rochester and the University of Copenhagen. Funding for the research came from the Lundbeck Foundation, the Novo Nordisk Foundation, Sana Biotechnology, the National Institute on Aging, the CHDI Foundation, and the Huntington’s Disease Golf Classic.
About this Huntington’s disease research news
Author: Mark Michaud
Source: University of Rochester
Contact: Mark Michaud – University of Rochester
Image: Image credit: Neuroscience News
Original research (open access): Human glial progenitors transplanted into Huntington disease mice normalize neuronal gene expression, dendritic structure, and behavior — Steve Goldman et al., Cell Reports
Abstract
Human glial progenitors transplanted into Huntington disease mice normalize neuronal gene expression, dendritic structure, and behavior
Neonatal glial replacement delays disease progression in mouse models of Huntington’s disease, where glial dysfunction is prominent. This study asked whether transplanting human glial progenitor cells (hGPCs) into adult R6/2 HD mice could improve phenotype and how healthy glia influence diseased host neurons. Introduction of hGPCs into adult R6/2 striata slowed motor and cognitive decline and extended survival. Single-nucleus RNA sequencing showed that genes associated with synaptic development and structure—downregulated in R6/2 striatal neurons—were partially rescued by healthy glia. Rabies labeling demonstrated that dendritic complexity and spine density, deficient in R6/2 neurons, were largely restored by hGPC engraftment. These results indicate that glial replacement in HD partially normalizes neuronal gene expression, restores dendritic structure, and delays disease progression.